[Malaria chemoprophylaxis in traveling children].
Arch Pediatr. 2005 Jan; 12(1):53-8.AP

Abstract

In France, 4,000 imported malaria cases are reported each year (7,000 to 8,000 estimated). Chemoprophylaxis is essential for prevention in travelers. When malaria is susceptible to chloroquine, this drug (Nivaquine) has to be used. It is given daily in France (1.5 mg/kg per day), from departure to four weeks after return. When low levels of chloroquino-resistance are reported, French authorities recommend the use of chloroquine + proguanil (Savarine) if the body weight is >50 kg or Nivaquine) + Paludrine), if <50 kg), or atovaquone + proguanil (Malarone). Nivaquine) (1.5 mg/kg per day) and Paludrine) (3 mg/kg per day) have to be pursued for one month after return, although Malarone) (1 pediatric tablet/10 kg per day, in children >10 kg weight) may be disrupted after one single week. Adverse events are rarer with atovaquone + proguanil, than with chloroquine + proguanil. When chloroquino-resistance is high, Malarone) or mefloquine (Lariam) are used. Weekly drug regimen is recommended with mefloquine (5 mg/kg per weight) for the travel duration and four weeks after return and the drug tolerance is good in pediatric prophylaxis. Doxycycline is used under conditions in children >8 years of age. New drugs as for tafenoquine, an amino-8 quinoleine, might enhance patients compliance if given monthly.

Links

Publisher Full Text

Authors+Show Affiliations

Minodier P
Accueil des urgences pédiatriques, CHU Nord, Chemin-des-Bourrelly, 13920 Marseille cedex 20, France. philippe.minodier@ap-hm.fr <philippe.minodier@ap-hm.fr>
Noël G
No affiliation info available
Blanc P
No affiliation info available
Tsaregorodtseva N
No affiliation info available
Retornaz K
No affiliation info available
Garnier JM
No affiliation info available

MeSH

AntimalarialsChildHumansMalariaTravel

Pub Type(s)

English Abstract
Journal Article
Review

Language

fre

PubMed ID

15653056